

Emit® 2000 Carbamazepine Assay

September 2011

4F052.2D_C

See shaded sections:

Updated information from September 2010 version.

Catalog Number	Product Description	Quantity/Volume
OSR4F229	Emit® 2000 Carbamazepine Assay	
	OSR4F518 R1 (Antibody/Substrate Reagent 1)	2 x 23 mL
	OSR4F548 R2 (Enzyme Reagent 2)	2 x 13 mL
4F109UL	Emit® 2000 Carbamazepine Calibrators*	1 x 5 mL†, 5 x 2 mL

* Required for calibrating the Emit® 2000 Carbamazepine Assay. Sold separately.

† Additional negative calibrator is provided.

Note: Reagents and calibrators are shipped ready to use in liquid form.

Note: Reagents 1 and 2 are provided as a matched set. They should not be interchanged with components of kits with different lot numbers.

The Emit® 2000 Carbamazepine Calibrators contain the following stated carbamazepine concentrations:

Calibrator	0	2	4	8	12	20
Carbamazepine (µg/mL)	0	2.0	4.0	8.0	12	20
Carbamazepine (µmol/L)	0	8.5	17	34	51	85

1 INTENDED USE

The Emit® 2000 Carbamazepine Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of carbamazepine in human serum or plasma. Measurements of carbamazepine are used as an aid in monitoring therapeutic administration of this drug. These reagents are packaged specifically for use on a variety of AU® Clinical Chemistry Systems.

2 SUMMARY

Monitoring serum carbamazepine concentrations, along with careful clinical assessment, is the most effective means of improving seizure control, reducing the risk of toxicity, and minimizing the need for additional anticonvulsant medication for the following reasons:^{1,2}

- Serum carbamazepine concentrations correlate better with pharmacologic activity than does dosage.
- Changes in carbamazepine's half-life with prolonged treatment and interindividual differences in carbamazepine metabolism make it difficult to predict serum levels from the administered dosage, particularly during concomitant therapy with other anticonvulsants. Serum level monitoring helps physicians individualize dosage regimens.
- Carbamazepine is safe and effective only in a narrow range of serum concentrations.

Carbamazepine-10,11-epoxide, a major metabolite of carbamazepine, is pharmacologically active and found in plasma and tissues.³ Methods historically used to monitor serum carbamazepine concentrations include gas-liquid chromatography, high-performance liquid chromatography, and immunoassay.^{1,2,4,5}

3 METHODOLOGY

The Emit® 2000 Carbamazepine Assay is a homogeneous enzyme immunoassay technique used for the analysis of specific compounds in biological fluids.^{5,6} The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically. Endogenous serum G6PDH does not interfere because the coenzyme functions only with the bacterial (*Leuconostoc mesenteroides*) enzyme employed in the assay.

4 REAGENTS

Reagents contain the following substances:

Mouse monoclonal antibodies reactive to carbamazepine (10 µg/mL), glucose-6-phosphate (22 mM), nicotinamide adenine dinucleotide (18 mM), carbamazepine labeled with glucose-6-phosphate dehydrogenase (0.22 U/mL), 0.1% sodium azide, Tris buffer, preservatives, and stabilizers.

Precautions

- For *in vitro* diagnostic use.
- Contains nonsterile mouse monoclonal antibodies.
- Assay components contain sodium azide, which may react with lead and copper plumbing to form highly explosive metal azides. If waste is discarded down the drain, flush the drain with a large volume of water to prevent azide buildup.
- Do not use the kit after the expiration date.
- This kit contains streptomycin sulfate. Please dispose of appropriately.
- Turbid or yellow reagents may indicate contamination or degradation and must be discarded.

Safety data sheets (MSDS/SDS) available on www.siemens.com/diagnostics

Preparation of Reagents

The Emit® 2000 Carbamazepine Assay reagents are provided ready to use; no preparation is necessary.

Storage of Assay Components

- Improper storage of reagents can affect assay performance.
- When not in use, store reagents upright at 2–8°C and with screw caps tightly closed.
- Unopened reagents are stable until the expiration date printed on the label if stored upright at 2–8°C.
- Do not freeze reagents or expose them to temperatures above 32°C.

5 SPECIMEN COLLECTION AND PREPARATION

- Each assay requires serum or plasma. Whole blood cannot be used. The anticoagulants heparin, citrate, oxalate, and EDTA have been tested and may be used with this assay. Some sample dilution may occur when samples are collected in tubes containing citrate anticoagulant. The amount of dilution and the possible need to correct for it should be considered when interpreting assay results for these samples.
- Sample volume is instrument-dependent. Refer to the appropriate Application Sheet for specific volumes.
- Store the serum or plasma refrigerated at 2–8°C. For transporting, maintain the sample temperature at 2–8°C. Samples can be stored refrigerated at 2–8°C for up to one month or stored frozen for up to three months.⁷
- Pharmacokinetic factors influence the correct time of sample collection after the last drug dose. These factors include dosage form, mode of administration, concomitant drug therapy, and biological variations affecting drug disposition.^{1,2}
- Measure the steady-state serum concentration representing the trough level just before the next scheduled dose.¹
- Human serum or plasma samples should be handled and disposed of as if they were potentially infectious.

6 PROCEDURE

Materials Provided

Emit® 2000 Carbamazepine Assay
Reagent 1
Reagent 2

Materials Required But Not Provided

Emit® 2000 Carbamazepine Calibrators
Multi-level commercial controls

Calibration

Recalibrate whenever a new lot of reagents is used or as indicated by control results (see Quality Control, below). If a new set of reagents with the same lot number is used, validate the system by assaying controls.

Quality Control

- Validate the calibration by assaying multi-level controls. Commercial controls are available for this purpose. Ensure that control results fall within acceptable limits as defined by your own laboratory. Once the calibration is validated, run samples.
- Follow government regulations or accreditation requirements for quality control frequency. At least once each day of use, analyze two levels of a Quality Control (QC) material with known carbamazepine concentrations. Follow your laboratory internal QC procedures if the results obtained are outside acceptable limits.
- Refer to the instrument User's Guide for appropriate instrument checks and maintenance instructions.

Diluting High Concentration Samples

To estimate carbamazepine concentrations above the assay range, patient samples containing more than 20 µg/mL (85 µmol/L) carbamazepine may be diluted with one or two parts distilled or deionized water or Emit® 2000 Carbamazepine Calibrator 0. After diluting the sample, repeat the entire assay sequence and multiply the results by the dilution factor. Some analyzers dilute and retest high concentration samples automatically. See the analyzer User's Guide or appropriate Application Sheet for instructions.

Evaluation and Interpretation of Results

- This assay uses Math Model No. 1.
- Results are automatically calculated; no additional manipulation of data is required.
- The factors that can influence the relationship between carbamazepine serum or plasma concentrations and clinical response include the type and severity of seizures, age, general state of health and use of other drugs.
- The concentration of carbamazepine in serum or plasma depends on the time of the last drug dose; mode of administration; concomitant drug therapy; sample condition; time of sample collection; and individual variations in absorption, distribution, biotransformation, and excretion. These parameters must be considered when interpreting results.^{1,2}
- Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

7 LIMITATIONS OF THE PROCEDURE

This assay has no specific limitations.

8 EXPECTED VALUES

The Emit® 2000 Carbamazepine Assay accurately quantitates carbamazepine concentrations in human serum or plasma containing 2.0–20 µg/mL (8.5–85 µmol/L) carbamazepine. The desired therapeutic effect is usually achieved in the serum concentration range of 4.0–12 µg/mL (17–51 µmol/L). Further, peak concentrations above 12 µg/mL (51 µmol/L) are often associated with toxicity.^{2,5}

Note: To convert from µg/mL to µmol/L carbamazepine, multiply by 4.23.

For effective treatment, some patients may require serum levels outside these ranges. Therefore, the expected range is provided only as a guide, and individual patient results should be interpreted in light of other clinical signs and symptoms (see Section 6, Procedure, Evaluation and Interpretation of Results).

9 SPECIFIC PERFORMANCE CHARACTERISTICS

The information presented in this section is based on Emit® 2000 Carbamazepine Assay studies performed on the AU400®/AU600® Clinical Chemistry System. Refer to the Application Sheets for other AU Clinical Chemistry Systems and for additional information. Results may vary due to analyzer-to-analyzer differences. The following performance characteristics represent total system performance and should not be interpreted to pertain only to reagents.

Endogenous Substances

No clinically significant interference has been found in samples to which 800 mg/dL hemoglobin, 750 mg/dL triglycerides, or 30 mg/dL bilirubin were added to simulate hemolytic, lipemic, or icteric samples.

Precision

Within-run precision was determined by assaying 20 replicates of each level of a tri-level control. Table 1 summarizes the data.

Table 1 — Within-run Precision

	Level 1	Level 2	Level 3
Mean (µg/mL)	4.72	10.49	15.33
%CV	2.9	2.2	2.2

Total precision was calculated according to NCCLS guideline EP5-T2 using data collected from controls run in duplicate twice daily over 20 days. Table 2 summarizes the data.

Table 2 — Total Precision

	Level 1	Level 2	Level 3
Mean (µg/mL)	4.42	10.15	14.97
%CV	6.3	4.8	6.5

Comparative Analysis

In this study, patient samples were analyzed on the TDx analyzer and on the AU600 Clinical Chemistry System. A summary of the results is as follows:

Slope		1.03
Intercept		0.35
Mean	TDx	7.22
	AU600	7.79
Correlation Coefficient		0.99
Number		57

Specificity

The Emit® 2000 Carbamazepine Assay measures the total (protein-bound plus unbound) carbamazepine concentration in serum or plasma. Compounds whose chemical structure or concurrent therapeutic use would suggest possible cross-reactivity have been tested.

The compounds listed in Table 3 do not interfere with the Emit® 2000 Carbamazepine Assay when tested in the presence of 8.0 µg/mL carbamazepine. Levels tested were at or above maximum physiological or pharmacological concentrations.

Table 3 — Compounds That Do Not Interfere

Compound	Concentration Tested (µg/mL)
Amitriptyline	5
Carbamazepine-10,11-epoxide	50
Chlorpromazine	8
Ethosuximide	500
Phenobarbital	500
Phenytoin	500
Primidone	200
Valproic Acid	1000

Sensitivity

















The sensitivity level of the Emit® 2000 Carbamazepine Assay is 0.5 µg/mL. This level represents the lowest measurable concentration of carbamazepine that can be distinguished from 0 µg/mL with a confidence level of 95%.

Calibration Stability

Studies have shown calibration stability of more than two weeks. When proper reagent handling, instrument maintenance, and operating procedures are followed, the calibration should remain stable for at least two weeks.

10 REFERENCES

1. MacKichan JJ, Kutt H. Carbamazepine: Therapeutic use and serum concentration monitoring. In: Taylor WJ, Finn AL, eds. *Individualizing Drug Therapy: Practical Applications of Drug Monitoring*. New York: Gross, Townsend, Frank, Inc; 1981, vol 2, pp 1–25.
2. Levy RH, Wilensky AJ, Friel PN. Other antiepileptic drugs. In: Evans WE, Schentag JJ, Jusko WJ, eds. *Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring*. Washington: Applied Therapeutics, Inc; 1987, pp 540–569.
3. Kutt H. Carbamazepine: Chemistry and methods of determination: Complex partial seizures and their treatment. *Adv Neurol* 1975;11:249–261.
4. Oles KS, Penry JK, Dyer RD. Evaluation of an enzyme immunoassay method for carbamazepine: A comparison with enzyme-multiplied immunoassay technique, fluorescence polarization immunoassay, and high-performance liquid chromatography. *Ther Drug Monit* 1989;11:471–476.
5. Pincus MR, Abraham NZ Jr. Toxicology and therapeutic drug monitoring. In: Henry JB, ed. *Clinical Diagnosis and Management by Laboratory Methods*, ed 18. Philadelphia: WB Saunders Co; 1991, pp 349–384.
6. Mulberg E. Syva Emit® 2000 Carbamazepine Assay, San Jose, CA, Syva Company.
7. Kumps AH. Therapeutic drug monitoring: A comprehensive and critical review of analytical methods for anticonvulsive drugs. *J Neurol* 1982;228:1–16.

Symbols Key	
	Do not reuse
	Use By
	Batch Code
	Catalogue Number
	Caution, consult accompanying documents
	Manufacturer
	Authorized Representative in the European Community
	Contains sufficient for <n> tests
	<i>In Vitro</i> Diagnostic Medical Device
	Temperature Limitation
	Consult Instructions for Use
	Non-sterile
	CE Mark
	Contents
	Reconstitution Volume
	Level

2010-07_BC

For technical assistance:

**Beckman Coulter customers contact their technical assistance center.
1-800-223-0130**

**Siemens Healthcare Diagnostics customers contact their technical assistance center.
1-800-227-8994 in the USA
1-800-264-0083 in Canada**

The Beckman Coulter logo and AU® are trademarks of Beckman Coulter, Inc.

The Syva logo and Emit® are trademarks of Siemens Healthcare Diagnostics.



Made in USA for
Beckman Coulter, Inc.
250 S. Kraemer Blvd.
Brea, CA 92821

